Why the study?
Prolongation of the QT interval is a serious adverse drug reaction that can lead to potentially life-threatening torsade de pointes, prompting an evaluation of QT-prolonging drug use and pharmacist recommendations during medication reviews in at-risk elderly individuals.
Do pharmacists adequately identify and provide recommendations for patients at high risk of QT interval prolongation during medication reviews?
Do pharmacists adequately identify and provide recommendations for patients at high risk of QT interval prolongation during medication reviews?
Pharmacists frequently miss opportunities to intervene on high-risk QT-prolonging drug regimens during medication reviews in elderly patients, highlighting a need for improved awareness.
Pharmacists may miss QT-prolonging risks in medication reviews; hypothesis-generating for education interventions to improve detection in elderly patients.
The prolongation of the QT interval is a relatively rare but serious adverse drug reaction. It can lead to torsade de pointes, which is potentially life-threatening. The study's objectives were: determine the use of QT interval-prolonging drugs in an elderly community-dwelling population at risk of medication misadventure and identify recommendations regarding the risk of QT interval prolongation made by pharmacists when performing medication reviews. In a retrospective evaluation, 500 medication review reports from Australian pharmacists were analysed. In patients taking at least one QT interval-prolonging drug, the individual risk of drug-induced QT interval prolongation was assessed. Recommendations of pharmacists to avoid the occurrence of this drug-related problem were examined. There was a high prevalence of use of potentially QT interval-prolonging drugs (71% patients), with 11% of patients taking at least one drug with a known risk. Pharmacists provided specific recommendations in only eight out of 35 patients (23%) with a high-risk score and taking drugs with known risk of QT interval prolongation. Pharmacists' recommendations, when present, were focused on drugs with known risk of QT interval prolongation, rather than patients' additional risk factors. There is a need to improve knowledge and awareness of this topic among pharmacists performing medication reviews.
No takes yet. Share an insight, caveat, or question.
Buss et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: